solu-cortef stungulyfsstofn og leysir, lausn 250 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg
tibolon orifarm tafla 2,5 mg
orifarm generics a/s - tibolonum inn - tafla - 2,5 mg
vivelle dot forðaplástur 100 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 100 míkróg
vivelle dot forðaplástur 25 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg
vivelle dot forðaplástur 37,5 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg
vivelle dot forðaplástur 50 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg
vivelle dot forðaplástur 75 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
solu-medrol stungulyfsstofn og leysir, lausn 125 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg
solu-medrol stungulyfsstofn og leysir, lausn 500 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg